Physician profile
Ronald N Gaster
NPI 1306940325
$7,110.26
in general payments reported to CMS, 2019-2025
25 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2020: $387 · 2021: $765 · 2022: $3,096 · 2023: $576 · 2024: $516 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $2,678.21 | 2019-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $459.64 | 2019 | |
| Carl Zeiss Meditec, INC. | $439.14 | 2019-2023 | |
| Oyster Point Pharma, INC. | $378.36 | 2022-2024 | Tyrvaya |
| Rxsight INC | $344.43 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Carl Zeiss Meditec USA, INC. | $306.26 | 2021 | |
| Mallinckrodt Hospital Products INC. | $275.40 | 2021-2024 | Acthar |
| Alcon Vision LLC | $266.97 | 2022-2025 | Rocklatan, Tryptyr |
| Glaukos Corporation | $231.59 | 2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Kala Pharmaceuticals, INC. | $212.91 | 2019-2020 | |
| Shire North American Group INC | $199.94 | 2019 | |
| Allergan, INC. | $179.55 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $179.48 | 2023-2024 | Miebo |
| Novartis Pharmaceuticals Corporation | $151.41 | 2019-2023 | |
| Eyepoint US, INC. | $125.00 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $124.72 | 2023 | Iheezo |
| Eyevance Pharmaceuticals LLC | $121.45 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $118.00 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $115.21 | 2023-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $81.32 | 2021 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Horizon Therapeutics Plc | $25.57 | 2021 | |
| Abbvie INC. | $22.71 | 2022 | |
| Ocular Therapeutix, INC. | $20.33 | 2020 | |
| Sight Sciences, INC. | $13.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Gaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.